scholarly journals Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

Brain ◽  
2017 ◽  
Vol 140 (9) ◽  
pp. 2426-2443 ◽  
Author(s):  
Tomas Kalincik ◽  
Ali Manouchehrinia ◽  
Lukas Sobisek ◽  
Vilija Jokubaitis ◽  
Tim Spelman ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Treatment Response ◽  
Personalized Therapy ◽  
Individual Treatment

A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis

2019 ◽  
Vol 26 (9) ◽  
pp. 1064-1073
Author(s):  
Fabio Pellegrini ◽  
Massimiliano Copetti ◽  
Francesca Bovis ◽  
David Cheng ◽  
Robert Hyde ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Personalized Medicine ◽  
Treatment Response ◽  
Short Form ◽  
Combined Treatment ◽  
Patient Specific ◽  
Individual Treatment ◽  
Treatment Groups ◽  
Relapsing Remitting ◽  
Relapsing Remitting Multiple Sclerosis

Background: Stratified medicine methodologies based on subgroup analyses are often insufficiently powered. More powerful personalized medicine approaches are based on continuous scores. Objective: We deployed a patient-specific continuous score predicting treatment response in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: Data from two independent randomized controlled trials (RCTs) were used to build and validate an individual treatment response (ITR) score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. Results: The ITR score for the combined treatment groups versus placebo detected differential clinical response in both RCTs. High responders in one RCT had a cross-validated ARR ratio of 0.29 (95% confidence interval (CI) = 0.13–0.55) versus 0.62 (95% CI = 0.47–0.83) for all other responders (heterogeneity p = 0.038) and were validated in the other RCT, with the corresponding ARR ratios of 0.31 (95% CI = 0.18–0.56) and 0.61 (95% CI = 0.47–0.79; heterogeneity p = 0.036). The strongest treatment effect modifiers were the Short Form-36 Physical Component Summary, age, Visual Function Test 2.5%, prior MS treatment and Expanded Disability Status Scale. Conclusion: Our modelling strategy detects and validates an ITR score and opens up avenues for building treatment response calculators that are also applicable in routine clinical practice.

35. Evoked potentials predict disease-modifying treatment response in multiple sclerosis

2013 ◽  
Vol 124 (11) ◽  
pp. e197
Author(s):  
L. Leocani ◽  
M. Bianco ◽  
G.Di Maggio ◽  
S. Medaglini ◽  
J. Gonzalez-Rosa ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Evoked Potentials ◽  
Treatment Response ◽  
Disease Modifying ◽  
Disease Modifying Treatment

Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis

2018 ◽  
Vol 323 ◽  
pp. 73-77 ◽  
Author(s):  
Silje Stokke Kvistad ◽  
Kjell-Morten Myhr ◽  
Trygve Holmøy ◽  
Jūratė Šaltytė Benth ◽  
Stig Wergeland ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Activity ◽  
Treatment Response ◽  
Serum Levels

Gender effects on treatment response to interferon-beta in multiple sclerosis

2014 ◽  
Vol 130 (6) ◽  
pp. 374-379 ◽  
Author(s):  
M. Magyari ◽  
N. Koch-Henriksen ◽  
B. Laursen ◽  
P. S. Sørensen
Keyword(s):  
Multiple Sclerosis ◽  
Treatment Response ◽  
Interferon Beta ◽  
Gender Effects
Sign in / Sign up

Export Citation Format

Share Document